{"id":"W2036532013","doi":"10.1016/j.jcte.2014.03.001","title":"Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical & Translational Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Novo Nordisk; Sanofi; Eli Lilly and Company","keywords":"Lixisenatide; Sitagliptin; Medicine; Internal medicine; Postprandial; Dipeptidyl peptidase-4 inhibitor; Metformin; Glucagon-like peptide 1 receptor; Hypoglycemia; Endocrinology; Type 2 Diabetes Mellitus; Glycated hemoglobin; Type 2 diabetes; Sitagliptin Phosphate; Gastroenterology; Adverse effect; Clinical endpoint; Liraglutide; Diabetes mellitus; Agonist; Randomized controlled trial; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00138665,0.0005671497,0.001949363,0.0003109234,0.0002435663,0.0006046045,0.0003377079,0.001098104,0.001575183],"category_scores_gemma":[0.001622799,0.000430794,0.001414112,0.0002334851,0.0005077861,0.0006762139,0.0002928179,0.001295122,0.0002760655],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003842496,"about_ca_system_score_gemma":0.0004810145,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003712534,"about_ca_topic_score_gemma":0.0008215186,"domain_scores_codex":[0.9995773,0.0002103505,0.0000637228,0.00005601219,0.00004363545,0.00004897954],"domain_scores_gemma":[0.9987161,0.0003740193,0.0002905516,0.00005464209,0.00005170933,0.0005130612],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9484686,0.01089098,0.004277658,0.0003411235,0.0008653636,0.00009797628,0.00008304179,0.0003545633,0.0109011,0.00004003036,0.0001714002,0.02350815],"study_design_scores_gemma":[0.3964017,0.5713964,0.0266687,0.00005747815,0.001350764,0.0001738743,0.00009146381,0.0008066171,0.00243046,0.00008699659,0.0004994617,0.00003611203],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9974854,0.001917987,0.00007536554,0.00006930205,0.00005730141,0.0001091675,0.00007528724,0.000009446689,0.0002007579],"genre_scores_gemma":[0.9971334,0.00135723,0.0002877397,0.0002717485,0.000120879,0.0001861095,0.0002113048,0.000004438129,0.0004272058],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001949363,"threshold_uncertainty_score":0.007333457,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01979462466269752,"score_gpt":0.2945601585356784,"score_spread":0.2747655338729809,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}